Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Humanetics has announced the successful completion of its Phase I human trial for BIO 300, a medical radiation countermeasure. BIO 300 is indicated for the prevention and mitigation of acute radiation syndrome.
Subscribe to our email newsletter
The company has said that the clinical trial successfully met all objectives and that BIO 300 was well tolerated at all dose levels which were studied. The completion of this trial is claimed to be an important milestone in further development of the drug.
Ronald Zenk, president and CEO of Humanetics, said: “Safety is the most important aspect in the development of any new drug. And since BIO 300 will likely be self-administered by civilians, we must be even more diligent in assuring the safety of this drug.”